Impact of Sex Differences on Patients with Neuroendocrine Neoplasms During Hospital Admission

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2024 Dec 17

PMID 39687054

Authors

Wan Ying Tan

Laura D Cramer

Namrata Vijayvergia

Maryam Lustberg

Pamela L Kunz

Affiliations

Soon will be listed here.

Abstract

Background: Sex disparities are known modifiers of health and disease. In neuroendocrine neoplasms (NENs), sex-based differences have been observed in the epidemiology and treatment-related side effects.

Objectives: To examine sex differences in demographics, diagnoses present during hospital admission, comorbidities, and outcomes of hospital course among hospitalized patients with NENs.

Design: Retrospective analysis.

Methods: A descriptive analysis of sex differences was performed on patients with NENs discharged from U.S. community hospitals in 2019 from the National Inpatient Sample (NIS), Healthcare Cost and Utilization Project, and Agency for Healthcare Research and Quality.

Results: A total of 7334 patients with NENs were identified; 4284 patients had primary NENs, and 3050 patients had metastatic NENs. In total, 48.7% were males and 51.3% were females. Distributions of race and ethnicity, and payer types differed by sex ( < 0.001 and = 0.027, respectively). For race and ethnicity, there were more females in White, Black, and Native American races, and Hispanic ethnicity. For payer types, female predominance was seen with Medicare, Medicaid, private insurance, and self-pay groups. Sex differences were seen in diagnosis made during hospital stay. In all NENs, oral ( = 0.036) and neurologic ( < 0.001) diagnoses were more common in females; ascites ( = 0.002), dysphagia ( = 0.002), biliary ductal obstruction ( = 0.014), and jaundice ( = 0.048) were more common in males. In primary NENs, ascites ( < 0.001) was male predominant. In metastatic NENs, dysphagia ( = 0.003) and jaundice ( = 0.034) were male predominant, whereas females had more headaches ( < 0.001). Nausea and vomiting were female predominant in all NENs ( < 0.001), primary ( = 0.044), and metastatic ( < 0.001) NENs. For comorbidities, arthropathies ( < 0.001), depression ( < 0.001), hypothyroidism ( < 0.001), other thyroid disorders ( < 0.001), chronic pulmonary disease ( = 0.002), and obesity ( < 0.001) were female predominant.

Conclusion: There were sex differences in the race and ethnicity, payer types, diagnoses present during hospital admission, and comorbidities among the 2019 NIS hospital discharge sample of patients with NENs.

References

Yao J, Hassan M, Phan A, Dagohoy C, Leary C, Mares J . One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377. View

Koizumi T, Otsuki K, Tanaka Y, Kanda S . Epidemiology of neuroendocrine neoplasmas in Japan: based on analysis of hospital-based cancer registry data, 2009 - 2015. BMC Endocr Disord. 2022; 22(1):105. PMC: 9022253. DOI: 10.1186/s12902-022-01016-4. View

Puthanmadhom Narayanan S, Anderson B, Bharucha A . Sex- and Gender-Related Differences in Common Functional Gastroenterologic Disorders. Mayo Clin Proc. 2021; 96(4):1071-1089. PMC: 8075061. DOI: 10.1016/j.mayocp.2020.10.004. View

Zheng R, Zhao H, An L, Zhang S, Chen R, Wang S . Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States. Chin Med J (Engl). 2023; 136(10):1216-1224. PMC: 10278748. DOI: 10.1097/CM9.0000000000002643. View

Unger J, Vaidya R, Albain K, LeBlanc M, Minasian L, Gotay C . Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. J Clin Oncol. 2022; 40(13):1474-1486. PMC: 9061143. DOI: 10.1200/JCO.21.02377. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

Mauvais-Jarvis F, Merz N, Barnes P, Brinton R, Carrero J, DeMeo D . Sex and gender: modifiers of health, disease, and medicine. Lancet. 2020; 396(10250):565-582. PMC: 7440877. DOI: 10.1016/S0140-6736(20)31561-0. View

Abdel-Rahman O, Fazio N . Sex-Based Differences in Prognosis of Patients With Gastroenteropancreatic-Neuroendocrine Neoplasms: A Population-Based Study. Pancreas. 2021; 50(5):727-731. DOI: 10.1097/MPA.0000000000001821. View

Abdel-Rahman O, Ghosh S, Morrish D . Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms. J Endocrinol Invest. 2022; 45(9):1683-1688. DOI: 10.1007/s40618-022-01805-7. View

10.

Muscogiuri G, Altieri B, Albertelli M, Dotto A, Modica R, Barrea L . Epidemiology of pancreatic neuroendocrine neoplasms: a gender perspective. Endocrine. 2020; 69(2):441-450. DOI: 10.1007/s12020-020-02331-3. View

11.

Xu Z, Wang L, Dai S, Chen M, Li F, Sun J . Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open. 2021; 4(9):e2124750. PMC: 8461504. DOI: 10.1001/jamanetworkopen.2021.24750. View

12.

Vaidya V, Partha G, Karmakar M . Gender differences in utilization of preventive care services in the United States. J Womens Health (Larchmt). 2011; 21(2):140-5. DOI: 10.1089/jwh.2011.2876. View

13.

Bertakis K, Azari R, Helms L, CALLAHAN E, Robbins J . Gender differences in the utilization of health care services. J Fam Pract. 2000; 49(2):147-52. View

14.

Huang T, Togun A, Boese T, Dowd B . Analysis of Affordable Health Care. Med Care. 2022; 60(9):718-725. DOI: 10.1097/MLR.0000000000001755. View

15.

Cukier M, Vergara R, Mendez-Rios J, Castillo O, Barrera I, Tello E . Neuroendocrine tumors in Panama: A nationwide database analysis. Mol Clin Oncol. 2021; 15(2):157. PMC: 8220651. DOI: 10.3892/mco.2021.2319. View

16.

Ozdemir B, Csajka C, Dotto G, Wagner A . Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology. J Clin Oncol. 2018; 36(26):2680-2683. DOI: 10.1200/JCO.2018.78.3290. View

17.

Oronsky B, Ma P, Morgensztern D, Carter C . Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia. 2017; 19(12):991-1002. PMC: 5678742. DOI: 10.1016/j.neo.2017.09.002. View

18.

Ivan S, Daniela O, Jaroslava B . Sex differences matter: Males and females are equal but not the same. Physiol Behav. 2022; 259:114038. DOI: 10.1016/j.physbeh.2022.114038. View

19.

Pinto M, Munoz Medel M, Carrillo D, Retamal I, Loreto Bravo M, Valenzuela Y . Chilean Registry for Neuroendocrine Tumors: A Latin American Perspective. Horm Cancer. 2018; 10(1):3-10. PMC: 6334732. DOI: 10.1007/s12672-018-0354-5. View

20.

Tsai H, Wu C, Tsai C, Lin S, Chen L, Chang J . The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One. 2013; 8(4):e62487. PMC: 3632554. DOI: 10.1371/journal.pone.0062487. View